MedTrace Logo

A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo

NCT07682506 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2026-08-11

No results posted yet for this study

Summary

This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.

Conditions

Interventions

DRUG

MH004 1.0% Ointment

MH004 1% ointment applied topically to the affected area as a thin film twice a day (BID).

DRUG

MH004 Placebo Ointment

MH004 Placebo ointment applied topically to the affected area as a thin film twice a day (BID).

Sponsors & Collaborators

  • Minghui Pharmaceutical (Hangzhou) Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-04
Primary Completion
2028-02-23
Completion
2028-10-04

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07682506 on ClinicalTrials.gov